Diagnosis & Therapy
Adding durvalumab immunotherapy to etoposide and platinum (EP) for the first-line treatment for extensive-stage small cell lung cancer (ES-SCLC) significantly improved 18-month overall survival, compared with EP alone, in the phase 3 CASPIAN trial.
Maintenance immunotherapy offers no added survival benefit in patients with extensive disease small cell lung cancer (ED-SCLC), according to results from the CheckMate 451 trial.
The immune checkpoint inhibitor pembrolizumab produced durable objective responses in some patients with extensive-stage small-cell lung cancer (SCLC) who had disease progression on two or more prior lines of therapy, data from two clinical trials showed.
Small-cell lung cancer (SCLC) is an extremely aggressive pulmonary malignancy with 5-year overall survival rates of just 5% to 10% with conventional therapeutic regimens.
Small-cell lung cancer (SCLC), in the words of one leading oncologist, is the “type of disease that gives cancer a bad name.”
Vaccine may restore NSCLC response to checkpoint inhibitorsBY CHRISTINE KILGORE MDedge News SAN FRANCISCO – An experimental allogeneic cellular vaccine combined with the checkpoint inhibitor nivolumab (Opdivo) may boost the immune response in patients with previously...
Neoadjuvant atezolizumab shrinks NSCLC tumorsBY CHRISTINE KILGORE MDedge News SAN FRANCISCO – One-fifth of patients with resectable non–small cell lung cancer had a major pathologic response to neoadjuvant therapy with the immune checkpoint inhibitor atezolizumab...
Interview with Roy S. Herbst, MD, PhD, on Immunotherapy in Lung CancerBY CHRISTINE KILGORE MDedge News Roy S. Herbst, MD, PhD, is the Ensign Professor of Medicine (Medical Oncology) and Professor of Pharmacology at Yale University, and Chief of Medical Oncology at...
Cost And Coping
Diagnosis and Therapy